[Isolated susceptibility of Streptococcus pyogenes to 3 macrolides]
Related Experiment Videos
1Infectious Disease Unit, HaEemek Medical Center, Afula.
Abstract:
Erythromycin is considered the drug of choice in the treatment of streptococcal pharyngitis in patients allergic to penicillin. However, in recent years several publications, especially in Finland and Italy, showed high resistance rates of S. pyogenes isolates to erythromycin and other new macrolides. To evaluate the situation in Israel, we checked the MIC of isolates from patients with tonsillitis during 1996. E-test results showed an MIC-50 of 0.23, 0.13 and 0.47 mcg/ml for erythromycin, clarithromycin and roxithromycin, respectively and a MIC-90 of 0.37, 0.23 and 0.78 mcg/ml. Only 2 isolates (2.1%) were partially or completely resistant to all 3 antibiotics. We conclude that empiric therapy with macrolides in Israel is still a viable option and can be recommended in S. pyogenes tonsillitis for patients allergic to penicillin.
Insights
Erythromycin is a top choice for penicillin-allergic patients with streptococcal pharyngitis. In Israel, macrolide antibiotics remain effective for treating S. pyogenes tonsillitis, showing low resistance rates.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Context:
- Streptococcal pharyngitis (S. pyogenes) treatment guidelines recommend erythromycin for penicillin-allergic patients.
- Recent European studies indicate rising macrolide resistance in S. pyogenes isolates.
- Evaluating current macrolide susceptibility in Israel is crucial for treatment recommendations.
Purpose:
- To assess the minimum inhibitory concentration (MIC) of erythromycin, clarithromycin, and roxithromycin against S. pyogenes isolates in Israel.
- To determine the prevalence of macrolide resistance in S. pyogenes causing tonsillitis in Israel.
Summary:
- Erythromycin, clarithromycin, and roxithromycin MIC-50 values were 0.23, 0.13, and 0.47 mcg/ml, respectively.
- MIC-90 values were 0.37, 0.23, and 0.78 mcg/ml for the respective macrolides.
- Only 2.1% of S. pyogenes isolates exhibited resistance to all three macrolides tested.
Impact:
- Macrolide antibiotics demonstrate low resistance rates in Israeli S. pyogenes isolates.
- Empiric macrolide therapy is a viable and recommended option for S. pyogenes tonsillitis in penicillin-allergic individuals in Israel.
- This study supports the continued use of macrolides for specific patient populations in Israel, contrasting with some international trends.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Streptococcal Pharyngitis
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis